PEPG Stock Analysis: Buy, Sell, or Hold?
PEPG - PepGen Inc. Common Stock
$1.76
-0.05 (-2.76%)
▼
5d:
+2.92%
30d:
+21.38%
90d:
+1.15%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PEPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PEPG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PEPG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PEPG is currently trading at $1.76, which is considered extended relative to its 30-day fair value range of $1.43 to $1.75.
Technical Outlook: Technically, PEPG is in a strong downtrend. The price is approaching resistance at $1.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PEPG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.25 (+482.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PEPG is in a strong downtrend. The price is approaching resistance at $1.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PEPG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.25 (+482.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.43 -
$1.75
Company Quality Score
57/100
(HOLD)
Options IV Signal
32th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 32th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 482.4% below Wall St target ($10.25)
Trading Range Analysis
30-Day Trading Range
$1.43 -
$1.75
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.50
(28.2%)
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.55
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.43
Wall Street Target
$10.25
(+482.4%)
Share & Embed Analysis
Last updated: July 04, 2026 1:14 AM ET
Data refreshes hourly during market hours. Next update: 2:14 AM
Data refreshes hourly during market hours. Next update: 2:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PEPG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
